{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:14:37Z","timestamp":1769357677710,"version":"3.49.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Preclinical studies suggest that exposure to prostate-directed local therapy (LT) may influence the efficacy of subsequent systemic therapy including androgen receptor pathway inhibitors. However, there is insufficient clinical evidence to support this premise in patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether exposure to prior prostate-directed LT (radical prostatectomy [RP], radiation therapy [RT], or both) played any effect-modifying role in the treatment effect of apalutamide on metastasis-free survival (MFS) and overall survival (OS) in patients with nmCRPC.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This post hoc secondary analysis used individual patient data from SPARTAN (Study of Apalutamide [ARN-509] in Men With Non-Metastatic Castration-Resistant Prostate Cancer), a phase 3, double-blinded, placebo-controlled randomized clinical trial conducted at 332 sites in 26 countries. Between October 14, 2013, and December 15, 2016, patients with nmCRPC and a prostate-specific antigen doubling time of 10 months or less were randomly assigned to apalutamide vs placebo; all patients received androgen deprivation therapy. The final data analysis was performed on December 31, 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Prior prostate-directed LT.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Separate Cox proportional hazards regression models were constructed for OS and MFS, which included prior LT, treatment group, and an interaction term, in addition to a minimally sufficient set of confounders. Adjusted hazard ratios (HRs) with 95% CIs for MFS and OS were determined for the apalutamide groups with or without prior LT.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 1179 evaluable patients included in this analysis, 795 received prior LT and 384 did not. The median age of patients with and without prior LT was 70 (IQR, 45-90) years and 75 (IQR, 50-95) years, respectively. The median follow-up was 52.0 (IQR, 51.5-52.8) months. A differential treatment effect of apalutamide on MFS was observed between patients with and without prior LT (P<\/jats:italic> for interaction\u2009=\u2009.009), with greater benefits for those with prior LT (adjusted HR, 0.22 [95% CI, 0.17-0.27]) compared with those without prior LT (adjusted HR, 0.35 [95% CI, 0.25-0.51]). However, there was insufficient evidence of a differential treatment effect on OS among subgroups stratified by exposure to prior LT (P<\/jats:italic> for interaction =\u2009.23), with improved OS in the subgroup with prior LT (adjusted HR, 0.72 [95% CI, 0.57-0.92]) but no significant difference in OS in the subgroup without prior LT (adjusted HR, 0.92 [95% CI, 0.64-1.31]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This post hoc analysis of the SPARTAN trial provides evidence of an interaction between prior LT and apalutamide in patients with nmCRPC, with a clinically significant and more favorable treatment effect from apalutamide on MFS among patients with prior LT. Further studies are needed to validate these findings.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01946204<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.39434","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:15:30Z","timestamp":1729005330000},"page":"e2439434","source":"Crossref","is-referenced-by-count":3,"title":["Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois"},{"name":"Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Malone","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Wing","sequence":"additional","affiliation":[{"name":"Usher Institute, University of Edinburgh, Edinburgh, United Kingdom"},{"name":"Public Health, School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and Sarah Cannon Research Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[{"name":"University Hospitals\u2013Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, University Hospital Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mohamad","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Y.","family":"Jia","sequence":"additional","affiliation":[{"name":"University Hospitals\u2013Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[{"name":"University Hospitals\u2013Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[{"name":"University Hospitals\u2013Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Surgery, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"4","key":"zoi241137r1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"zoi241137r2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer.","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"issue":"4","key":"zoi241137r3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euo.2021.05.009","article-title":"Drug development for prostate cancer with biochemical recurrence: trials and tribulations.","volume":"4","author":"Sayegh","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"zoi241137r4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/pcm-21-34","article-title":"The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review.","volume":"5","author":"Vidal","year":"2022","journal-title":"Precis Cancer Med"},{"issue":"2","key":"zoi241137r5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer.","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"10","key":"zoi241137r6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy.","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi241137r7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer.","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi241137r8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi241137r9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer.","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi241137r10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer.","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"zoi241137r11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030593","article-title":"Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies.","volume":"9","author":"Puca","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"APR","key":"zoi241137r12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fonc.2015.00090","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.","volume":"5","author":"Hu","year":"2015","journal-title":"Front Oncol"},{"issue":"1","key":"zoi241137r13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40659-018-0180-9","article-title":"Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.","volume":"51","author":"Murray","year":"2018","journal-title":"Biol Res"},{"issue":"8989","key":"zoi241137r14","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(95)92054-4","article-title":"Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy.","volume":"346","author":"Eschw\u00e8ge","year":"1995","journal-title":"Lancet"},{"issue":"8","key":"zoi241137r15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10585-009-9284-5","article-title":"Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples.","volume":"26","author":"Cawthorn","year":"2009","journal-title":"Clin Exp Metastasis"},{"issue":"8","key":"zoi241137r16","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-17-2332","article-title":"CXCL12? promotes metastatic castration-resistant prostate cancer by inducing cancer stem cell and neuroendocrine phenotypes.","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res"},{"issue":"6","key":"zoi241137r17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/pros.22945","article-title":"Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.","volume":"75","author":"Gong","year":"2015","journal-title":"Prostate"},{"issue":"2","key":"zoi241137r18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/genes8020071","article-title":"Therapeutic approaches targeting MYC-driven prostate cancer.","volume":"8","author":"Rebello","year":"2017","journal-title":"Genes (Basel)"},{"issue":"6","key":"zoi241137r19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.eururo.2023.02.017","article-title":"Effect of prior local therapy on response to first-line androgen receptor axis targeted therapy in metastatic castrate-resistant prostate cancer: a secondary analysis of the COU-AA-302 trial.","volume":"83","author":"Roy","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"zoi241137r20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.01.003","article-title":"Effect of prior prostate directed local therapy on response to apalutamide in metastatic hormone sensitive prostate cancer: a secondary analysis of the TITAN study.","volume":"85","author":"Roy","year":"2024","journal-title":"Eur Urol"},{"issue":"8","key":"zoi241137r21","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13145","article-title":"Understanding of interaction (subgroup) analysis in clinical trials.","volume":"49","author":"Brankovic","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"zoi241137r22","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/EDE.0000000000000752","article-title":"R function for additive interaction measures.","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"6","key":"zoi241137r23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/aje\/kwn411","article-title":"Estimation of the relative excess risk due to interaction and associated confidence bounds.","volume":"169","author":"Richardson","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi241137r24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10654-011-9554-9","article-title":"Estimating measures of interaction on an additive scale for preventive exposures.","volume":"26","author":"Knol","year":"2011","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"zoi241137r25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model.","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"1","key":"zoi241137r26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/rssb.12027","article-title":"Covariate balancing propensity score.","volume":"76","author":"Imai","year":"2014","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"1","key":"zoi241137r27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/biomet\/79.1.139","article-title":"Fitting Cox\u2019s proportional hazards models from survey data.","volume":"79","author":"Binder","year":"1992","journal-title":"Biometrika"},{"issue":"1","key":"zoi241137r28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1214\/aos\/1176345335","article-title":"A large sample study of Cox\u2019s regression model.","volume":"9","author":"Tsiatis","year":"1981","journal-title":"Ann Stat"},{"key":"zoi241137r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v009.i08","article-title":"Analysis of complex survey samples.","volume":"9","author":"Lumley","year":"2004","journal-title":"J Stat Softw"},{"issue":"23","key":"zoi241137r30","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1158\/0008-5472.CAN-08-2229","article-title":"Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.","volume":"68","author":"Deng","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"zoi241137r31","first-page":"834","article-title":"Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.","volume":"1","author":"Deng","year":"2011","journal-title":"Am J Cancer Res"},{"issue":"2","key":"zoi241137r32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3892\/ijo.2015.3274","article-title":"Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.","volume":"48","author":"Grossebrummel","year":"2016","journal-title":"Int J Oncol"},{"issue":"1","key":"zoi241137r33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2967\/jnumed.120.245456","article-title":"PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.","volume":"62","author":"Weber","year":"2021","journal-title":"J Nucl Med"},{"issue":"24","key":"zoi241137r34","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer.","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi241137r35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer.","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi241137r36","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1097\/01.ju.0000118907.64125.e0","article-title":"Racial\/ethnic disparities in the treatment of localized\/regional prostate cancer.","volume":"171","author":"Underwood","year":"2004","journal-title":"J Urol"},{"key":"zoi241137r37","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002570.05","article-title":"MP27-05: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer patients with and without prior local therapy with radical prostatectomy or radiotherapy.","volume":"207","author":"Siemens","year":"2022","journal-title":"J Urol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824884\/roy_2024_oi_241137_1727980015.16704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:15:32Z","timestamp":1729005332000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824884"}},"subtitle":["A Secondary Analysis of the SPARTAN Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.39434","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}